INTRODUCTION
The incidence of leptomeningeal metastasis (LM), also known as carcinomatous meningitis or leptomeningeal carcinomatosis, typically varies by primary tumor type, occurring in approximately 5% to 8% of patients with solid tumors and 5% to 15% of patients with hematologic malignancies. 1 Although it can also be identified in hematologic malignancies and primary brain tumors, such as gliomas, medulloblastomas, and ependymomas, this review will focus on involvement of the subarachnoid space and leptomeninges (arachnoid and pia mater) by solid tumors. Dural involvement can also occur; however, because the dura is not protected by the blood-brain barrier (BBB), treatment is not subject to the same limitations as leptomeningeal involvement and falls outside the scope of this review. Nonetheless, it is important to note that leptomeningeal involvement is often identified concurrently with parenchymal or dural disease. LM usually confers a poor prognosis, with an average survival of 2 to 4 months despite treatment, although response to treatment can vary, with some patients surviving significantly longer. 1 Although treatment options remain limited, advances in the molecular and genetic understanding of systemic malignancies have yielded new opportunities for clinically effective therapies and better tools to predict therapeutic response.
PATHOGENESIS AND EPIDEMIOLOGY
Unfortunately, understanding of disease pathogenesis has not improved markedly since LM was initially described in the late 19th century. 2 Recent studies have started to shed light on the pathogenesis, however, with 1 study demonstrating that cancer cells within the cerebrospinal fluid (CSF) upregulate the production of complement component 3. 3 This, in turn, leads to disruption of the BBB and entry of plasma growth factors into the CSF, promoting cancer cell growth. Cancerous involvement of the leptomeninges is thought to occur by several mechanisms, including direct extension from brain parenchyma, dura, or bone; hematologic spread, particularly through venous plexi and/or perineural extension. LM involvement most commonly occurs in the basal cisterns of the brain, posterior fossa, and cauda equina. 4, 5 Invasion of the leptomeninges can lead to local inflammation and impaired CSF resorption, which can then obstruct CSF flow and cause hydrocephalus and/or increased intracranial pressure.
Although nearly every systemic tumor has been reported to metastasize to the leptomeninges, common solid tumors include lung, breast, and melanoma. Incidence varies by tumor type and ranges from 5% to 8% of metastatic breast cancers, 6 from 9% to 25% of lung cancers (greater in small cell lung cancer), 7 and from 6% to 18% of melanomas. 8 Overall, the incidence of LM may be increasing in the setting of improved systemic control and treatments that poorly penetrate the BBB, leading to longer survival and a reservoir of tumor cells in the central nervous system (CNS). [9] [10] [11] [12] [13] Progressive systemic disease is also observed in 60% to 70% of patients at the time of LM diagnosis. 14, 15 In a large case series of 187 patients, including 150 patients with solid malignancies (primarily breast and lung cancers), 58% had concurrent or prior parenchymal brain involvement. 16 The median time from systemic cancer diagnosis to the diagnosis of LM ranges from 1.2 to 2.0 years in solid tumors and averages 11 months in hematologic malignancies. 14, 16, 17 CLINICAL PRESENTATION AND DIFFERENTIAL DIAGNOSIS Signs and symptoms of LM depend on the location of involvement. Given the frequent multifocality, clinical presentation may be nonspecific, and the index of suspicion must be high. Common clinical findings are often attributable to cranial and spinal nerve dysfunction, increased intracranial pressure (ICP), or meningeal irritation (Table 1) . Cranial nerves VI, VII, and VIII are commonly affected, leading to diplopia, facial weakness, and changes in hearing, respectively. Spinal signs include dermatomal sensory loss, radicular pain, bowel and bladder dysfunction, and limb weakness. Other general symptoms include headache, nausea, vomiting, and changes in mental status. Involvement or compression of small vessels in the subarachnoid space may also lead to ischemic infarct.
Given the broad presenting features and frequently complex treatment histories, consideration should also be given to alternative diagnoses, including chronic infectious meningitis, autoimmune disorders (eg, sarcoidosis), meningeal reaction to brain abscess, side effects of chemotherapy or radiation, paraneoplastic syndromes, and toxic-metabolic encephalopathy (Table 2 ). In immunocompromised cancer patients, causes of infectious meningitis or encephalitis include bacterial (eg, tuberculosis, listeriosis), fungal (eg, Cryptococcus, candidiasis), or viral (eg, cytomegalovirus, varicella zoster virus, Epstein-Barr virus, herpes simplex virus, and JC virus). 18 
DIAGNOSTIC EVALUATION
The diagnosis of LM remains challenging, with no test sufficiently sensitive to rule out involvement. Magnetic resonance imaging (MRI) of the brain and spine is recommended if there is clinical suspicion and may reveal leptomeningeal enhancement, which is often irregular and nodular (Fig. 1) . 19 Subependymal deposits and hydrocephalus may also be seen. Imaging should be interpreted with caution if a recent lumbar puncture has been performed because resulting low ICP or inflammation may lead to transient enhancement. The sensitivity of MRI with gadolinium is approximately 70%, with specificity of 77% to 100% (higher for solid tumors than for hematologic malignancies). [20] [21] [22] In the presence of typical clinical features, an abnormal MRI is sufficient to make the diagnosis. 22 111-Indium or 99-technetium ventriculography may be performed to evaluate CSF flow in select Cancer circumstances when this may help guide treatment, as described below.
If it is safe to perform, then lumbar puncture is recommended ( Fig. 2) and often reveals mild pleocytosis with elevated protein and hypoglycorrhachia. In cases of profound hypoglycorrhachia, infectious etiologies (described above) should be considered, particularly bacterial and fungal meningitis. An elevated opening pressure may be observed in 50% to 70% of patients, depending on the extent of leptomeningeal involvement. 23 Falsenegative cytology results can be minimized in several ways. 17 First, sufficient CSF volume of at least 10 mL should be obtained for cytologic analysis. Second, the CSF specimen should be processed as soon as possible to reduce the risk of cell death. Glantz et al reported a falsenegative error rate of 36% in samples that were refrigerated for 48 hours versus samples collected from the same patients that had positive cytology upon immediate processing. Third, obtaining CSF from a site of known leptomeningeal disease may increase the likelihood of detecting abnormal cells, although this may be more relevant in untreated patients who are screened for LM than in those who have received intrathecal (IT) or systemic treatment. Finally, the procedure should be repeated at least once if the initial sample is negative and LM is suspected. CSF cytology is positive in >90% of patients with suspected LM after 3 high-volume lumbar punctures with a specificity of >95%. 15, 24 False-positive results may be obtained in infectious or other inflammatory conditions with reactive lymphocytes. Flow cytometry and additional 
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Cancer molecular studies may be valuable in select clinical scenarios. Flow cytometry has increased sensitivity compared to cytomorphologic analysis in the setting of hematologic malignancies. 25 The use of CSF tumor markers has been limited by their low sensitivity and specificity as well as significant assay variability. However, these markers may support the diagnosis in the face of an otherwise equivocal diagnostic evaluation. In particular, CSF levels >1% of serum levels of specific tumor markers, such as carcinoembryonic antigen (CEA) from adenocarcinomas, a-fetoprotein from hepatocellular and testicular carcinomas, and b-human chorionic gonadotropin from choriocarcinoma and testicular carcinomas, are relatively specific for CSF involvement. 26, 27 These markers may also have value in following response to treatment. More recently, cell-free DNA present in the CSF has been used to detect tumorspecific somatic alterations through next-generation sequencing. [28] [29] [30] The detection of tumor-specific mutations may increase the sensitivity and specificity of diagnostic CSF evaluation, aid in the assessment of treatment response, and shed light on mechanisms of CNS resistance to systemic therapy. Finally, if there is no known active, systemic disease, then systemic restaging should be performed as this may guide further treatment.
ASSESSING RESPONSE TO THERAPY
Of the 6 randomized controlled trials (Table 3) 31-36 conducted in LM, most have incorporated neurologic examination and CSF cytology to determine response to treatment. However, assessment of neurologic response was often based on subjective neurologic evaluations, MRI criteria were not used or were not stated, and cytologic evaluation was not uniform. 37 The site of CSF sampling is also important in assessing response because negative cytology at 1 site (eg, through an Ommaya reservoir) does not necessarily define a cytologic response when the initial diagnosis was made based on cytologic evaluation at another site (eg, lumbar puncture). Primary endpoints varied across trials, including overall survival, neurologic response rate, time to neurologic progression, and progression-free survival. Secondary endpoints included neurologic progression, neurologic response rate, safety and toxicity profile, cause of death, Karnofsky performance status (KPS) evolution over time, quality of life, LM-specific survival, and overall survival. Secondary endpoints, such as patient-reported quality of life and neurologic progression, may be important considerations for settings in which disease is often advanced and overall survival is unlikely to be prolonged, but symptom palliation remains a central goal of therapy.
Standardized assessment was only recently proposed by the Response Assessment in Neuro-Oncology (RANO) Group in 2016 after recognition of the limitations in assessing outcomes. 38 The proposed criteria include a standard neurologic examination, MRI of the brain and spine, and CSF evaluation. Therapeutic response can only be determined in the setting of a negative cytologic evaluation (as well as flow cytometry in hematologic malignancies), definite improvement in CNS imaging, decreased or absent steroid dose (in hematologic malignancies only), and improved symptoms. It is important to note that definitive worsening of CNS imaging is sufficient to determine progressive or refractory disease. Response based on CSF cytology is considered when cytology converts from positive to negative at all sites that were previously positive and is subsequently confirmed after 1 month. Of note, there was a lack of consensus regarding response determination in a patient with persistently positive cytology in the setting of stable or improved clinical and radiographic status. Although suggested, the criteria do not include patient-reported outcomes, such as the MD Anderson Cancer Center Symptom Inventory Brain Tumor Module (MDASI-BT), the MD Figure 2 . This is a diagnostic algorithm of the current study. MRI indicates magnetic resonance imaging.
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Anderson Cancer Center Symptom Inventory Spine Tumor Module (MDASI-SP), or the Functional Assessment of Cancer Therapy-Brain. These experts acknowledge that the proposed criteria to standardize LM response assessment require validation and refinement; however, the criteria serve as a new standard that can be incorporated into future clinical trials to enable better comparisons across trials and more rigorous assessment of therapeutic response.
PROGNOSIS
Despite advances in care, the prognosis for patients with LM remains poor, with an overall survival of approximately 2 to 4 months from the time of diagnosis if treated.
1 Untreated, death occurs from progressive neurologic deterioration in 4 to 6 weeks. 15 A KPS > 70, chemosensitivity of primary cancer, unimpaired CSF flow, CSF protein levels <50 mg/dL, and active treatment have been identified as favorable prognostic factors. 39, 40 One study of patients who had solid and hematologic malignancies and cytologically confirmed LM demonstrated that those with a KPS 70 had a median survival of 15.5 weeks compared with 6 weeks in those with a KPS <70. 40 The US National Comprehensive Cancer Network (NCCN) identifies poor prognostic factors as a KPS <60, severe neurologic deficits, extensive systemic disease with few treatment options, bulky CNS disease, and encephalopathy. 41 Primary tumor type also plays an important role. In 1 patient series, those with hematologic 16 Within solid tumors, breast cancer LM has a superior prognosis compared to other tumor types, with a median survival of 5 to 7 months. 16, [42] [43] [44] [45] TREATMENT The treatment of LM has traditionally been directed toward palliation, although new therapies have produced promising response rates. While systemic chemotherapies have been limited in their ability to cross the BBB, they are often combined with radiation and other palliative surgical interventions with the goal of preventing neurologic deterioration, maintaining quality of life, and prolonging survival. IT chemotherapy is frequently considered; however, clinical trial data are limited. Because of the paucity of prospective, randomized trials, optimum therapy is poorly defined, and treatment is mostly guided by expert opinion.
Radiation
Radiation is typically geared toward symptom management and thus often targets bulky, symptomatic sites of disease, particularly in the spine. Frequently, whole-brain radiotherapy at doses between 30 to 40 grays (Gy) in 2-Gy to 3-Gy fractions is administered, although an abbreviated course of 20 Gy in 4-Gy fractions is sometimes considered in patients with a poor prognosis or who are less likely to tolerate treatment. 26, 46 Radiation may also restore CSF flow and relieve hydrocephalus by reducing tumor bulk and, in doing so, facilitate the use of IT chemotherapy. 47 In addition to the long-term side effects of radiotherapy alone, there may also be an increased risk of late leukoencephalopathy when combined with other chemotherapeutic agents, such as intravenous or IT methotrexate. 35, [48] [49] [50] [51] [52] Radiation is unlikely to prolong survival based on retrospective studies in patients with breast and lung cancers, but it can result in rapid symptom improvement. 53, 54 Eradication of tumor cells from the leptomeninges would require craniospinal irradiation, which carries significant potential CNS and systemic toxicities, including myelosuppression, that may compromise future cytotoxic chemotherapy options. In addition, it is often considered impractical in the setting of a poor overall prognosis. Although it is not standard practice, craniospinal irradiation may be used in the setting of LM from hematologic malignancies because these are frequently highly radiosensitive. 50, 55, 56 
IT Chemotherapy
Although IT delivery of chemotherapy bypasses the BBB and minimizes systemic side effects, it is not without limitations. Agents can be administered by lumbar puncture or through surgical placement of a reservoir that directly feeds into the ventricular system through a catheter (such as an Ommaya reservoir). Commonly used agents include methotrexate (a folate antagonist), thiotepa (an alkylating agent), cytarabine (a pyrimidine analog), and sustainedrelease liposomal cytarabine (DepoCyt; Pacira Pharmaceuticals, Inc, San Diego, California). Several retrospective studies have demonstrated a survival benefit from IT therapy. 45, 47 Of the 6 randomized clinical trials conducted in LM, all focused on IT therapy (Table 3) . It is important to note that most trials and series excluded patients who were deemed too sick for treatment, which may constitute a significant proportion of patients at presentation. The study by Boogerd et al 35 was the only trial to compare IT chemotherapy with standard therapy without IT treatment. In 35 patients who had breast cancer, with 17 randomized to receive IT chemotherapy, there was no difference in survival or neurologic response, and the trial was closed prematurely because of low accrual. Another retrospective study of 104 patients with LM from any solid tumor who received systemic therapy and radiation with or without IT therapy also demonstrated no difference in median survival. 51 Quality-of-life measures were not assessed in either study, and both studies reported increased rates of treatment-related neurotoxicity in patients who received IT chemotherapy. A study of liposomal cytarabine in breast cancer LM is currently underway (clinicaltrials.gov identifier NCT01645839).
Aseptic or chemical meningitis is one of the more common complications observed in up to 43% of patients and characterized by sterile CSF pleocytosis as well as clinical signs and symptoms of meningitis. 57, 58 Although Chamberlain et al observed that the frequency of this complication was independent of the type of IT chemotherapy administered through Ommaya reservoirs (between methotrexate, cytarabine, and thiotepa), because of the frequent occurrence of chemical arachnoiditis with IT liposomal cytarabine, it is now standard to coadminister it with dexamethasone. 57 Corticosteroids and intravenous hydration can be used to treat and mitigate the symptoms of this complication. However, infectious meningitis should be ruled out when aseptic meningitis is considered and is present in 8% to 24% of patients receiving intraventricular therapy. 59 The most common organism is Staphylococcus epidermidis, and treatment requires intravenous and intraventricular antibiotics; removal of
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Cancer the reservoir may be indicated as well. 60, 61 Other complications of IT chemotherapy include leukoencephalopathy (particularly when combined with radiation), myelopathy, seizure, and inadvertent subdural or epidural delivery if administered by lumbar puncture. Despite the method of administration, myelosuppression can also be observed in up to 18% of patients. 57 The site and pattern of involvement are important issues when considering IT chemotherapy. Penetration is limited in areas of bulky leptomeningeal disease, to approximately 2 to 3 mm. 58 If there is evidence of complete or partial obstruction of CSF flow, then excessive build-up of the chemotherapy may lead to neurotoxicity and treatment failure. Radionucleotide flow studies may be helpful to evaluate CSF flow before therapy. However, these studies are more invasive than conventional imaging and are often technically challenging, requiring cisternograms immediately after tracer injection as well as 4 to 6, 24, 48, and sometimes even 72 hours after injection. 62 In the setting of ventriculoperitoneal shunts (VPS), there are also concerns about the accumulation of chemotherapy leading to neurotoxicity should there be shunt malfunction or intraperitoneal toxicity from draining of the IT drug. However, a small retrospective study demonstrated that IT chemotherapy could safely be administered through a reservoir-on/off valve VPS. 63 
Systemic Chemotherapy
Although systemic chemotherapy is limited by the ability of agents to penetrate the BBB, there is breakdown of the BBB in the setting of LM, and it has been demonstrated that several chemotherapies can achieve therapeutic levels in the CSF when administered systemically. In addition, systemic chemotherapy does not depend on CSF flow, is able to penetrate bulky nodular disease, concurrently addresses any systemically active disease, and avoids the potential procedural complications associated with IT therapy. The type of malignancy should guide the choice of systemic chemotherapy. Options include high-dose methotrexate (3-8 g/m) 64, 65 high-dose cytarabine (3 g/m) 66,67 capecitebine (particularly for breast cancer), [68] [69] [70] [71] thiotepa, 72 and temozolomide. 73 Response has also been reported with highdose etoposide in 5 patients with LM from small cell lung cancer. 74 Systemic chemotherapy, particularly when combined with radiation, can lead to acute or delayed leukoencephalopathy, subacute encephalopathy, and acute cerebellar syndrome associated with high-dose cytarabine.
Numerous retrospective studies have demonstrated improved survival in patients who received systemic chemotherapy. [42] [43] [44] 75, 76 Some argue that, based on the randomized trial by Boogerd et al 35 and other retrospective studies, IT chemotherapy adds little value to systemic chemotherapy. 35, 51, 64, 77 Conversely, however, a prospective series of patients with LM from nonsmall cell lung cancer (NSCLC) identified no added survival benefit from systemic chemotherapy when combined with radiotherapy and intraventricular chemotherapy. 47 The role of systemic versus IT chemotherapy may vary based on primary tumor type, as the studies that demonstrated little added value from IT therapy primarily consisted of patients with lymphoma or breast cancer.
Targeted Therapies
Melanoma
In subsets of solid tumors, targeted therapies have demonstrated promising results. Approximately 50% of melanomas harbor an activating mutation in the v-Raf murine sarcoma viral oncogene homolog B (BRAF), most commonly BRAF V600E (valine-to-glutamic acid mutation at position 600), which constitutively activates the mitogenactivated protein kinase pathway. In LM from melanoma, there are reports of response to BRAF inhibitors such as vemurafenib 78 and dabrafenib. 79 Most mechanisms of resistance to BRAF inhibition are mediated through mitogen-activated protein kinase kinase (MEK), and 3 randomized phase 3 studies in metastatic melanoma have now demonstrated the superiority of combined BRAF and MEK inhibition compared with BRAF inhibition alone. [80] [81] [82] This strategy has not been evaluated in patients with LM involvement to date, although all 3 trials included patients with stable brain metastases.
Breast cancer
Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 30% of primary breast cancers and is associated with an increased risk of CNS involvement. 83 Multiple reports describe response to IT trastuzumab, a humanized monoclonal antibody against HER2, in LM from HER2-positive breast cancer. [84] [85] [86] [87] [88] [89] Preliminary results from a phase 1 trial of IT trastuzumab in patients with HER2-positive breast cancer and LM demonstrated that it was well tolerated, and several phase 2 trials are ongoing (clinicaltrials.gov identifiers NCT01325207 and NCT01373710). 90 Combination approaches are also being studied, with a phase 1 trial of lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) that targets HER2 and EGFR, in combination with capecitabine, an antimetabolite chemotherapeutic, currently underway in HER2-positive patients with LM (clinicaltrials.gov identifier NCT02650752). The phase 2 In NSCLC, first-generation TKIs like erlotinib and gefitinib do not readily cross the BBB and may be actively removed by drug efflux proteins. 92, 93 However, CSF concentrations may reach therapeutic levels at high doses. 92 Although there have been no randomized trials, responses have been described to erlotinib [94] [95] [96] [97] [98] [99] [100] [101] [102] and gefitinib, 103, 104 particularly at high doses. Several retrospective studies have reported prolonged survival in EGFR-mutant patients who had NSCLC with LM treated with firstgeneration EGFR TKIs. 105, 106 It is believed that secondgeneration and third-generation EGFR TKIs have better BBB penetration. A report of patients with pretreated EGFR-mutant NSCLC and brain metastases or LM who received afatinib on a compassionate use basis indicated a 35% response rate and CSF concentrations of up to 1 nMol. 107 Additional case reports support the efficacy of afatinib in patients with LM who have progressed on firstgeneration TKIs. 108, 109 Preliminary data for the thirdgeneration TKI omesartinib (AZD9291) in heavily pretreated patients with EGFR-mutant NSCLC and LM suggest promising response rates (7 of 12 patients had radiographic improvement, 8 of 9 patients had decreased EGFR messenger DNA copy numbers). 110 It is noteworthy that EGFR mutation status in the primary tumor and metastasis may be discordant, and an analysis should be performed on CSF if possible. 92, 111, 112 There is an ongoing phase 2 clinical trial of tesevatinib, a BBB-penetrant oral TKI, in patients with EGFR-activating mutations and brain or leptomeningeal metastases (clinicaltrials.gov identifier NCT02616393).
Anaplastic lymphoma kinase (ALK) rearrangements are another important therapeutic target in NSCLC and are associated with an increased risk of CNS involvement. 113, 114 The presence of an ALK rearrangement confers sensitivity to ALK TKIs. Data suggest that secondgeneration inhibitors have improved BBB penetration compared with the first-generation inhibitor crizotinib. Several case reports have documented responses in LM with alectinib and ceritinib in patients with crizotinibresistant disease. [114] [115] [116] The efficacy of ceritinib in treating LM in patients with ALK-rearranged NSCLC is being further evaluated in an ongoing phase 2 clinical trial (clinicaltrials.gov identifier NCT02336451).
Supportive Care
Symptomatic management should always be pursued in addition to any disease-directed therapies. Because symptoms may be caused by inflammation as well as direct tumor involvement, steroids may play a role in symptom management, although the role of steroids is often greater in the setting of LM secondary to hematologic malignancies. Nausea, vomiting, and headache should be treated with appropriate medications; if present, seizures should be controlled with antiepileptic drugs. Fatigue related to treatment, particularly radiation, may be alleviated by psychostimulants. If there are clinical signs of increased ICP, such as nausea, headache, or encephalopathy, then a high-volume lumbar puncture should be pursued. If pressure is elevated, then a palliative VPS should be considered. 117 Pain due to cranial and spinal nerve involvement can be managed with palliative focal radiation, opioids, or opioid-sparing agents but, unfortunately, is often refractory in the setting of a poor response to treatment of the underlying disease.
Novel Approaches
Given the remarkable response to checkpoint inhibitors in many systemic malignancies, multiple clinical trials (Table 4) are underway to evaluate their efficacy in the setting of LM, including pembrolizumab (clinicaltrials.gov identifierNCT02886585) and combination ipilimumab and nivolumab for melanoma LM (clinicaltrials.gov identifier NCT02939300). Immune-based approaches are often associated with inflammation, which, even if transient, may contribute to significant neurotoxicity in the CNS. For example, despite responses observed with IT interleukin-2 and interferon a, both were associated with significant CNS toxicity (particularly signs of meningitis, edema, and increased ICP), limiting their widespread use. 118, 119 To date, there has been only 1 case report of the anticytotoxic T-lymphocyte-associated protein 4 antibody ipilimumab combined with whole-brain radiotherapy demonstrating efficacy in a patient with melanoma LM. 120 Intrathecally delivered monoclonal antibodies against tumor-specific antigens have also been studied as a means to selectively deliver radiation (also known as radioimmunotherapy) and/or therapeutic agents. Although the approach was first studied the 1980s, it has regained interest with the renewed focus on targeted and immune-based therapies. Retrospective data and prior phase 1 trials suggest therapeutic safety and efficacy in LM across several tumor types, with particular activity observed in LM from primitive neuroectodermal tumors. 121, 122 More recently, a A phase 2 trial of this agent is ongoing (clinicaltrials.gov identifier NCT00445965). This approach, as with other IT therapies, is limited by toxicities, such as myelosuppression, aseptic meningitis, and increased ICP. Similar to other targeted therapies, this approach is also limited by the availability of tumor-specific antibodies. There is an ongoing phase 1 clinical trial of 131-I-labeled 8H9, an antibody that targets the glycoprotein 4Ig-B7H3, which is present on a broad spectrum of solid tumors, in patients with refractory brain or leptomeningeal disease (clinicaltrials.gov identifier NCT00089245). Novel clinical trial designs are allowing for the recruitment of patients across malignancy subtypes, often based on molecular characteristics shared across many cancers. For example, the phase 2 clinical trial for the cyclin-dependent kinase inhibitor abemaciclib includes patients with LM from breast cancer, NSCLC, or melanoma, with a particular focus on hormone receptor-positive patients (clinicaltrials. gov identifier NCT02308020). This approach may be particularly beneficial in an uncommon disease like LM, which has historically been excluded from clinical trials and is infrequent enough that accrual to dedicated trials in a single tumor subtype is prohibitively slow. CONCLUSION LM continues to remain one of the most challenging complications of cancer in terms of diagnostic complexity, poor prognosis, often devastating impact on quality of life, and mixed response to standard cytotoxic and targeted therapies. Treatment to date has been limited by effective drug delivery as well as toxicity; consequently, it is clear that not all patients benefit from currently available therapies. Improved diagnostic tools and better biomarkers may allow for earlier diagnosis and treatment, thereby improving outcomes. After diagnosis, optimum treatment continues to be based mostly on expert consensus because of a paucity of clinical trials. An improved understanding of the biologic mechanisms underlying tumor metastasis and the molecular features of metastatic disease compared with the primary site will allow for the testing of more targeted treatment strategies in subsets of patients most likely to benefit. Improved patient-derived xenograft models of brain metastases and LM will also assist in the discovery of new therapeutic agents and mechanisms of resistance to therapy. Evaluation of the efficacy of new treatments will be facilitated by novel trial designs and molecular-based patient selection, which have led to increased recruitment of patients with LM into clinical trials. The newly proposed RANO criteria for assessing leptomeningeal disease will help standardize response evaluation across clinical trials, although the criteria will need to be prospectively validated, and quality-of-life measures should be considered moving forward.
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